Testing effectiveness (Phase 2)Looking for participantsNCT06799065
What this trial is testing
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Who this might be right for
Advanced Solid TumorsBreast Cancer RecurrentOvarian Cancer+4 more
Accent Therapeutics 218